Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Disease progression meta‐analysis model in Alzheimer's disease

Ito, Kaori, Ahadieh, Sima, Corrigan, Brian, French, Jonathan, Fullerton, Terence, Tensfeldt, Thomas, Alzheimer's Disease Working Group · 2010 · Alzheimer's & Dementia

Abstract

Background: Various authors have evaluated disease progression in Alzheimer's disease (AD), using patient data from individual clinical studies or pooled data across various trials. We conducted a systematic review of public data sources from 1990 to 2008 for all available AChE inhibitor studies, as well as clinical studies that evaluated the rate of deterioration in AD patients. Unique to this analysis, we developed a model based on literature data to describe the longitudinal response in the Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐cog) (change from baseline) in mild to moderate severity AD patients. The model was used to estimate disease progression for both placebo‐treated patients and acetylcholinesterase (AChE)‐inhibitor treated patients, and factors that affected disease progression. Methods: We collected 576 mean ADAS‐cog changes from baseline data points of 52 trials, representing data from approximately 19,972 patients and more than 84,000 individual observations. The model described the rate of disease progression, the evident placebo effect, and the symptomatic effect of AChE‐inhibitors. Baseline ADAS‐cog, Mini‐Mental State Examination score, age, and year of publication were tested as covariates. Results: The disease progression in mild to moderate AD patients across all available and relevant literature sources was estimated as 5.5 points per year. An Emax‐type model best described the symptomatic drug effect of AChE inhibitors. The rate of disease progression (underlying disease progression) was no different between placebo and AChE‐inhibitors groups. Baseline ADAS‐cog is a significant covariate in disease progression. Baseline age was also tested as a covariate in the rate of disease progression, but the model was unable to describe any effects of age, likely because of the narrow distribution of mean age (literature‐level analysis). There was no significant impact of publication year in the model. Conclusions: Baseline ADAS‐cog is a significant covariate affecting the rate of disease progression, and it describes or at least explains the different rates of deterioration evident in early or late stages of the disease. There was no significant impact of publication year in the model, suggesting that disease progression has not slowed in more recent trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2009.05.665

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 181

Metadata

Authors
Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T., Tensfeldt, T., & Alzheimer's Disease Working Group
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2009-07-10
Volume
6
Issue
1
Pages
39-53
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2133556574
Cited by
181
References
8
FWCI
7.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease progression meta‐analysis model in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2009.05.665
The paper
Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T., Tensfeldt, T., & Alzheimer's Disease Working Group. (2010). Disease progression meta‐analysis model in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2009.05.665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.